Global Chronic Heart Failure (CHF) Drugs Market

Chronic Heart Failure (CHF) Drugs Comprehensive Study by Type (Anti-clotting (Aspirin), Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor), Anticoagulant Medicines (Warfarin), Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors), Angiotensin II Receptor Blockers (ARB), Statins, Diuretics, Nitrates), Drugs (Brand, Generic), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other) Players and Region - Global Market Outlook to 2028

Chronic Heart Failure (CHF) Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Chronic Heart Failure (CHF) Drugs Market Overview:
The modernized facilities reduced the physical activities, the stress level among the people are also rising and the Increasing prevalence of cardiovascular diseases, technological advancements, and an increasing number of cardiovascular drugs. Thus, these factors are leading to cardiovascular conditions and are leading to rising demand for cardiovascular drugs. Chronic heart failure is a condition or a collection of symptoms in which the heart isn't pumping enough blood to meet the body's needs. Heart failure usually develops slowly after an injury to the heart. alone. According to the research healthcare expenditures in the United States on heart failure are estimated to be aroundUSD 39 billion per year, making it one of the largest expenses to the healthcare system. With the ageing of the population, Medtronic estimates that the number of patients with heart failure could exceed eight million by 2030.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
The incidences are rising due to the shift in the lifestyle and the other health conditions due to the change in the adoption of the modernized facilities

Market Growth Drivers:
The growing ageing population of both industrialized and developing nations and Growing incidence of obesity, diabetes, and hypertension

Challenges:
Entrance of new players in the market

Restraints:
High cost associated with the chronic heart failure (CHF) drugs

Opportunities:
Growth opportunities in the developing nations and Heart failure prevalence is rising throughout the world

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Abbott (United States), Novartis International AG (Switzerland), Stanley Pharmaceuticals (Pakistan), Johnson & Johnson (United States), GlaxoSmithKline plc (United Kingdom), Merck (United States), Bristol-Myers Squibb Company (United States), Pfizer (United States), New Haven Pharmaceuticals, Inc. (United States), Biovail Corporation (Canada) and Symplmed Pharmaceuticals (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Chronic Heart Failure (CHF) Drugs market by 2028. Considering Market by , the sub-segment i.e. will boost the Chronic Heart Failure (CHF) Drugs market.

Latest Market Insights:
In 2020, Novartis announced a new program to assist patients in low-income and lower-middle-income countries (LIC; LMIC) in obtaining cheap drugs to treat the principal symptoms of COVID-19, which is a pressing need in the absence of a vaccine or curative treatment.

What Can be Explored with the Chronic Heart Failure (CHF) Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Chronic Heart Failure (CHF) Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Chronic Heart Failure (CHF) Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Chronic Heart Failure (CHF) Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Chronic Heart Failure (CHF) Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Chronic Heart Failure (CHF) Drugs Providers, Government Regulatory and Research Organizations, Hospitals and End Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Anti-clotting (Aspirin)
  • Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor)
  • Anticoagulant Medicines (Warfarin)
  • Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors)
  • Angiotensin II Receptor Blockers (ARB)
  • Statins
  • Diuretics
  • Nitrates
By Drugs
  • Brand
  • Generic

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The growing ageing population of both industrialized and developing nations
      • 3.2.2. Growing incidence of obesity, diabetes, and hypertension
    • 3.3. Market Challenges
      • 3.3.1. Entrance of new players in the market
    • 3.4. Market Trends
      • 3.4.1. The incidences are rising due to the shift in the lifestyle and the other health conditions due to the change in the adoption of the modernized facilities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chronic Heart Failure (CHF) Drugs, by Type, Drugs, Distribution Channel and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Chronic Heart Failure (CHF) Drugs (Value)
      • 5.2.1. Global Chronic Heart Failure (CHF) Drugs by: Type (Value)
        • 5.2.1.1. Anti-clotting (Aspirin)
        • 5.2.1.2. Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor)
        • 5.2.1.3. Anticoagulant Medicines (Warfarin)
        • 5.2.1.4. Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors)
        • 5.2.1.5. Angiotensin II Receptor Blockers (ARB)
        • 5.2.1.6. Statins
        • 5.2.1.7. Diuretics
        • 5.2.1.8. Nitrates
      • 5.2.2. Global Chronic Heart Failure (CHF) Drugs by: Drugs (Value)
        • 5.2.2.1. Brand
        • 5.2.2.2. Generic
      • 5.2.3. Global Chronic Heart Failure (CHF) Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Other
      • 5.2.4. Global Chronic Heart Failure (CHF) Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Chronic Heart Failure (CHF) Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Stanley Pharmaceuticals (Pakistan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bristol-Myers Squibb Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. New Haven Pharmaceuticals, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Biovail Corporation (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Symplmed Pharmaceuticals (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Chronic Heart Failure (CHF) Drugs Sale, by Type, Drugs, Distribution Channel and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Chronic Heart Failure (CHF) Drugs (Value)
      • 7.2.1. Global Chronic Heart Failure (CHF) Drugs by: Type (Value)
        • 7.2.1.1. Anti-clotting (Aspirin)
        • 7.2.1.2. Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor)
        • 7.2.1.3. Anticoagulant Medicines (Warfarin)
        • 7.2.1.4. Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors)
        • 7.2.1.5. Angiotensin II Receptor Blockers (ARB)
        • 7.2.1.6. Statins
        • 7.2.1.7. Diuretics
        • 7.2.1.8. Nitrates
      • 7.2.2. Global Chronic Heart Failure (CHF) Drugs by: Drugs (Value)
        • 7.2.2.1. Brand
        • 7.2.2.2. Generic
      • 7.2.3. Global Chronic Heart Failure (CHF) Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Other
      • 7.2.4. Global Chronic Heart Failure (CHF) Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chronic Heart Failure (CHF) Drugs: by Type(USD Million)
  • Table 2. Chronic Heart Failure (CHF) Drugs Anti-clotting (Aspirin) , by Region USD Million (2017-2022)
  • Table 3. Chronic Heart Failure (CHF) Drugs Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor) , by Region USD Million (2017-2022)
  • Table 4. Chronic Heart Failure (CHF) Drugs Anticoagulant Medicines (Warfarin) , by Region USD Million (2017-2022)
  • Table 5. Chronic Heart Failure (CHF) Drugs Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors) , by Region USD Million (2017-2022)
  • Table 6. Chronic Heart Failure (CHF) Drugs Angiotensin II Receptor Blockers (ARB) , by Region USD Million (2017-2022)
  • Table 7. Chronic Heart Failure (CHF) Drugs Statins , by Region USD Million (2017-2022)
  • Table 8. Chronic Heart Failure (CHF) Drugs Diuretics , by Region USD Million (2017-2022)
  • Table 9. Chronic Heart Failure (CHF) Drugs Nitrates , by Region USD Million (2017-2022)
  • Table 10. Chronic Heart Failure (CHF) Drugs: by Drugs(USD Million)
  • Table 11. Chronic Heart Failure (CHF) Drugs Brand , by Region USD Million (2017-2022)
  • Table 12. Chronic Heart Failure (CHF) Drugs Generic , by Region USD Million (2017-2022)
  • Table 13. Chronic Heart Failure (CHF) Drugs: by Distribution Channel(USD Million)
  • Table 14. Chronic Heart Failure (CHF) Drugs Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 15. Chronic Heart Failure (CHF) Drugs Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 16. Chronic Heart Failure (CHF) Drugs Other , by Region USD Million (2017-2022)
  • Table 17. South America Chronic Heart Failure (CHF) Drugs, by Country USD Million (2017-2022)
  • Table 18. South America Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 19. South America Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 20. South America Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 21. Brazil Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 22. Brazil Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 23. Brazil Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 24. Argentina Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 25. Argentina Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 26. Argentina Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 27. Rest of South America Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 28. Rest of South America Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 29. Rest of South America Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 30. Asia Pacific Chronic Heart Failure (CHF) Drugs, by Country USD Million (2017-2022)
  • Table 31. Asia Pacific Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 32. Asia Pacific Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 33. Asia Pacific Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 34. China Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 35. China Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 36. China Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 37. Japan Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 38. Japan Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 39. Japan Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 40. India Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 41. India Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 42. India Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 43. South Korea Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 44. South Korea Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 45. South Korea Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 46. Taiwan Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 47. Taiwan Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 48. Taiwan Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 49. Australia Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 50. Australia Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 51. Australia Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 54. Rest of Asia-Pacific Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 55. Europe Chronic Heart Failure (CHF) Drugs, by Country USD Million (2017-2022)
  • Table 56. Europe Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 57. Europe Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 58. Europe Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 59. Germany Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 60. Germany Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 61. Germany Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 62. France Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 63. France Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 64. France Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 65. Italy Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 66. Italy Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 67. Italy Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 68. United Kingdom Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 69. United Kingdom Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 70. United Kingdom Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 71. Netherlands Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 72. Netherlands Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 73. Netherlands Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 74. Rest of Europe Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 75. Rest of Europe Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 76. Rest of Europe Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 77. MEA Chronic Heart Failure (CHF) Drugs, by Country USD Million (2017-2022)
  • Table 78. MEA Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 79. MEA Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 80. MEA Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 81. Middle East Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 82. Middle East Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 83. Middle East Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 84. Africa Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 85. Africa Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 86. Africa Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 87. North America Chronic Heart Failure (CHF) Drugs, by Country USD Million (2017-2022)
  • Table 88. North America Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 89. North America Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 90. North America Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 91. United States Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 92. United States Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 93. United States Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 94. Canada Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 95. Canada Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 96. Canada Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 97. Mexico Chronic Heart Failure (CHF) Drugs, by Type USD Million (2017-2022)
  • Table 98. Mexico Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2017-2022)
  • Table 99. Mexico Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Chronic Heart Failure (CHF) Drugs: by Type(USD Million)
  • Table 112. Chronic Heart Failure (CHF) Drugs Anti-clotting (Aspirin) , by Region USD Million (2023-2028)
  • Table 113. Chronic Heart Failure (CHF) Drugs Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor) , by Region USD Million (2023-2028)
  • Table 114. Chronic Heart Failure (CHF) Drugs Anticoagulant Medicines (Warfarin) , by Region USD Million (2023-2028)
  • Table 115. Chronic Heart Failure (CHF) Drugs Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors) , by Region USD Million (2023-2028)
  • Table 116. Chronic Heart Failure (CHF) Drugs Angiotensin II Receptor Blockers (ARB) , by Region USD Million (2023-2028)
  • Table 117. Chronic Heart Failure (CHF) Drugs Statins , by Region USD Million (2023-2028)
  • Table 118. Chronic Heart Failure (CHF) Drugs Diuretics , by Region USD Million (2023-2028)
  • Table 119. Chronic Heart Failure (CHF) Drugs Nitrates , by Region USD Million (2023-2028)
  • Table 120. Chronic Heart Failure (CHF) Drugs: by Drugs(USD Million)
  • Table 121. Chronic Heart Failure (CHF) Drugs Brand , by Region USD Million (2023-2028)
  • Table 122. Chronic Heart Failure (CHF) Drugs Generic , by Region USD Million (2023-2028)
  • Table 123. Chronic Heart Failure (CHF) Drugs: by Distribution Channel(USD Million)
  • Table 124. Chronic Heart Failure (CHF) Drugs Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 125. Chronic Heart Failure (CHF) Drugs Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 126. Chronic Heart Failure (CHF) Drugs Other , by Region USD Million (2023-2028)
  • Table 127. South America Chronic Heart Failure (CHF) Drugs, by Country USD Million (2023-2028)
  • Table 128. South America Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 129. South America Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 130. South America Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 131. Brazil Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 132. Brazil Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 133. Brazil Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 134. Argentina Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 135. Argentina Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 136. Argentina Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 137. Rest of South America Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 138. Rest of South America Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 139. Rest of South America Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 140. Asia Pacific Chronic Heart Failure (CHF) Drugs, by Country USD Million (2023-2028)
  • Table 141. Asia Pacific Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 142. Asia Pacific Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 143. Asia Pacific Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 144. China Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 145. China Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 146. China Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 147. Japan Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 148. Japan Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 149. Japan Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 150. India Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 151. India Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 152. India Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 153. South Korea Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 154. South Korea Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 155. South Korea Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 156. Taiwan Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 157. Taiwan Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 158. Taiwan Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 159. Australia Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 160. Australia Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 161. Australia Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 162. Rest of Asia-Pacific Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 163. Rest of Asia-Pacific Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 164. Rest of Asia-Pacific Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 165. Europe Chronic Heart Failure (CHF) Drugs, by Country USD Million (2023-2028)
  • Table 166. Europe Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 167. Europe Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 168. Europe Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 169. Germany Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 170. Germany Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 171. Germany Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 172. France Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 173. France Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 174. France Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 175. Italy Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 176. Italy Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 177. Italy Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 178. United Kingdom Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 179. United Kingdom Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 180. United Kingdom Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 181. Netherlands Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 182. Netherlands Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 183. Netherlands Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 184. Rest of Europe Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 185. Rest of Europe Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 186. Rest of Europe Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 187. MEA Chronic Heart Failure (CHF) Drugs, by Country USD Million (2023-2028)
  • Table 188. MEA Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 189. MEA Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 190. MEA Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 191. Middle East Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 192. Middle East Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 193. Middle East Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 194. Africa Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 195. Africa Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 196. Africa Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 197. North America Chronic Heart Failure (CHF) Drugs, by Country USD Million (2023-2028)
  • Table 198. North America Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 199. North America Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 200. North America Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 201. United States Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 202. United States Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 203. United States Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 204. Canada Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 205. Canada Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 206. Canada Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 207. Mexico Chronic Heart Failure (CHF) Drugs, by Type USD Million (2023-2028)
  • Table 208. Mexico Chronic Heart Failure (CHF) Drugs, by Drugs USD Million (2023-2028)
  • Table 209. Mexico Chronic Heart Failure (CHF) Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 210. Research Programs/Design for This Report
  • Table 211. Key Data Information from Secondary Sources
  • Table 212. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chronic Heart Failure (CHF) Drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Chronic Heart Failure (CHF) Drugs: by Drugs USD Million (2017-2022)
  • Figure 6. Global Chronic Heart Failure (CHF) Drugs: by Distribution Channel USD Million (2017-2022)
  • Figure 7. South America Chronic Heart Failure (CHF) Drugs Share (%), by Country
  • Figure 8. Asia Pacific Chronic Heart Failure (CHF) Drugs Share (%), by Country
  • Figure 9. Europe Chronic Heart Failure (CHF) Drugs Share (%), by Country
  • Figure 10. MEA Chronic Heart Failure (CHF) Drugs Share (%), by Country
  • Figure 11. North America Chronic Heart Failure (CHF) Drugs Share (%), by Country
  • Figure 12. Global Chronic Heart Failure (CHF) Drugs share by Players 2022 (%)
  • Figure 13. Global Chronic Heart Failure (CHF) Drugs share by Players (Top 3) 2022(%)
  • Figure 14. Global Chronic Heart Failure (CHF) Drugs share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 17. Abbott (United States) Revenue: by Geography 2022
  • Figure 18. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis International AG (Switzerland) Revenue: by Geography 2022
  • Figure 20. Stanley Pharmaceuticals (Pakistan) Revenue, Net Income and Gross profit
  • Figure 21. Stanley Pharmaceuticals (Pakistan) Revenue: by Geography 2022
  • Figure 22. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 23. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 24. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 26. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 27. Merck (United States) Revenue: by Geography 2022
  • Figure 28. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 29. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2022
  • Figure 30. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer (United States) Revenue: by Geography 2022
  • Figure 32. New Haven Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. New Haven Pharmaceuticals, Inc. (United States) Revenue: by Geography 2022
  • Figure 34. Biovail Corporation (Canada) Revenue, Net Income and Gross profit
  • Figure 35. Biovail Corporation (Canada) Revenue: by Geography 2022
  • Figure 36. Symplmed Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 37. Symplmed Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 38. Global Chronic Heart Failure (CHF) Drugs: by Type USD Million (2023-2028)
  • Figure 39. Global Chronic Heart Failure (CHF) Drugs: by Drugs USD Million (2023-2028)
  • Figure 40. Global Chronic Heart Failure (CHF) Drugs: by Distribution Channel USD Million (2023-2028)
  • Figure 41. South America Chronic Heart Failure (CHF) Drugs Share (%), by Country
  • Figure 42. Asia Pacific Chronic Heart Failure (CHF) Drugs Share (%), by Country
  • Figure 43. Europe Chronic Heart Failure (CHF) Drugs Share (%), by Country
  • Figure 44. MEA Chronic Heart Failure (CHF) Drugs Share (%), by Country
  • Figure 45. North America Chronic Heart Failure (CHF) Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott (United States)
  • Novartis International AG (Switzerland)
  • Stanley Pharmaceuticals (Pakistan)
  • Johnson & Johnson (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Merck (United States)
  • Bristol-Myers Squibb Company (United States)
  • Pfizer (United States)
  • New Haven Pharmaceuticals, Inc. (United States)
  • Biovail Corporation (Canada)
  • Symplmed Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


May 2023 201 Pages 81 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Chronic Heart Failure (CHF) Drugs Market Quantitative research analysis
Global Chronic Heart Failure (CHF) Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Chronic Heart Failure (CHF) Drugs market are Abbott (United States), Novartis International AG (Switzerland), Stanley Pharmaceuticals (Pakistan), Johnson & Johnson (United States), GlaxoSmithKline plc (United Kingdom), Merck (United States), Bristol-Myers Squibb Company (United States), Pfizer (United States), New Haven Pharmaceuticals, Inc. (United States), Biovail Corporation (Canada) and Symplmed Pharmaceuticals (United States), to name a few.
"The incidences are rising due to the shift in the lifestyle and the other health conditions due to the change in the adoption of the modernized facilities" is seen as one of major influencing trends for Chronic Heart Failure (CHF) Drugs Market during projected period 2022-2028.
Anti-clotting (Aspirin) segment in Global market to hold robust market share owing to "The growing ageing population of both industrialized and developing nations ".

Know More About Global Chronic Heart Failure (CHF) Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Propantheline Bromide Comprehensive Study by Application (Hyperhidrosis, Enuresis, Cramps or spasms of the stomach, Intestines or bladder), Drug type (Generic Drug, Patented Drug), Distribution Cha...
$ 3450
Lisinopril  Comprehensive Study by Patient Age (Paediatric (6 to 17 years), Adult (above 18 years)), Form (Solution, Tablet), Sales Channel (Online, Offline, Hospital Pharmacy, Retail Pharmacy), Dosa...
$ 3500
Dosulepin Comprehensive Study by Type (Tablets (75mg), Capsules (25mg)), Application (Depression Treatment, Anxiety Treatment, Others), Distribution Channel (Hospital, Drug Store, Online Store) Playe...
$ 3500
Adenovirus Vector Vaccine Comprehensive Study by Type (Adenovirus-based tuberculosis vaccine, Adenovirus-based HIV vaccine, Adenovirus-based influenza vaccine, Others), Application (Human, Animals), ...
$ 3450
Goserelin Drug Comprehensive Study by Indication (Prostate Cancer, Breast Cancer, Endometriosis, Gynaecological Disorders), Sales Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), Dose (...
$ 3500
Paediatric Palliative Care Drugs Comprehensive Study by Type (Paracetamol, Ibuprofen, Morphine, Others), Route of Administration (Oral, Topical, Parenteral), Distribution Channel (Hospital Pharmacies...
$ 3450